The early predictive value of frailty for health-related quality of life among elderly patients with cancer receiving curative chemotherapy.

Changes in health-related quality of life (HRQOL) among elderly patients with cancer before and after receiving curative treatment, such as chemotherapy, have always been an important consideration in physician-patient treatment decision-making. Although frailty assessment can help predict the effects of chemotherapy, there is a lack of relevant literature on its effectiveness in predicting post-chemotherapy HRQOL. Therefore, this study investigated the early predictive value of pre-chemotherapy frailty assessment for post-chemotherapy HRQOL among elderly patients with cancer receiving curative chemotherapy. From September 2016 to November 2018, this study enrolled elderly patients with cancer aged ≥ 65 years (N = 178), who were expected to receive chemotherapy at three hospitals in Taiwan. The mean age of patients was 71.70 years (SD = 5.46 years) and half of them were female (n = 96, 53.9%). A comprehensive geriatric assessment was performed to measure frailty in 178 participants one week before receiving chemotherapy (T0). Further, the HRQOL of the elderly patients with cancer was assessed again, four weeks after chemotherapy (T1). After controlling for demographic variables, this study evaluated the predictive value of frailty for HRQOL using a hierarchical regression analysis. A total of 103 (57.9%) participants met the frailty criteria. The results showed that 31.1%-56.7% of the variance in the seven domains of HRQOL could be explained by demographic variables and the presence or absence of frailty. This suggests that the presence or absence of frailty is an important predictor of the illness burden domain (ß = 9.5; p < .05) of HRQOL. Frailty affects the illness burden domain of HRQOL in elderly patients with cancer. Finally, the administration of frailty assessments before treatment is recommended as a reference for patient treatment decision-making.

Assessment of Platelet Activation and Immature Platelet Fraction as Predictors of Platelet Engraftment After Hematopoietic Stem Cell Transplantation.

Delayed platelet engraftment is a well-known complication of umbilical cord blood transplantation (CBT). Megakaryocytes derived from cord blood (CB) in vitro are smaller than megakaryocytes derived from bone marrow (BM) in adults. A small megakaryocyte size might contribute to delayed megakaryocytic maturation. This study included 37 patients undergoing hematopoietic stem cell transplantation (HSCT) at Chang Gung Children's Hospital between July 2011 and June 2013. Blood samples were obtained at different times: preconditioning and post-HSCT days 56 and 97. To test whether platelet activation persists posttransplantation, two commonly used platelet activation marker antibodies, CD62P (P-selectin) and CD42b, were evaluated using whole blood flow cytometry, combining thiazole orange and anti-CD41a staining, to assess reticulated platelets. Serial peripheral blood (PB) samples were obtained posttransplantation from patients undergoing CBT (CBT group; n = 15) and mobilized peripheral blood transplantation (PBT group; n = 22). Platelet activation in the postengraftment samples was considerably higher in the PBT group than the CBT group. Moreover, immature platelet fractions (IPF) were higher in the CBT group. Our results emphasize the role of IPF for dynamic prediction of platelet engraftment in CBT.

Intention, needs, and expectations of cancer patients participating in clinical trials.

BACKGROUND: Clinical trials provide information for developing new treatment strategies, enhancing cancer knowledge, and improving trial effectiveness. However, factors related to patients' participation in clinical trials have not been explored in Taiwan. OBJECTIVES: This study explored cancer patients' willingness to participate in clinical trials and motivational factors, barriers, needs, expectations, and other factors influencing their decision making. METHODS: In this cross-sectional study, information was collected using structured questionnaires with cancer patients from an academic medical center. RESULTS: Among 184 cancer patients sampled, most (87.5%) were willing to participate in a clinical trial. Their attitude toward participating in clinical trials was positive (average motivational score = 59.09; highest scoring item was "chance of cure"). Participants had a slight barrier level for participating in clinical trials (average barrier score = 21.51; highest scoring item was "concern over adverse effects of drugs used in clinical trials"). They had strong needs for clinical trial participation (average need factors score = 59.24; highest scoring need item was "supply of clinical trial-related information by medical personnel, including study purpose, adverse effects, effectiveness, and notices"). Participants had expectations of clinical trial participation (average expectations score = 66.58; highest scoring item was "nonrecurrence of tumor"). Factors predicting participation in clinical trials included medical issues and subjective viewpoint. CONCLUSIONS: These study results can help clinical researchers understand cancer patients' willingness to participate in clinical trials and other influencing factors. IMPLICATIONS FOR PRACTICE: Clinical research nurses can use this information in discussions with cancer patients and important stakeholders to help eligible patients better understand clinical trials to make informed decisions about participation.

Traumatic superior orbital fissure syndrome: assessment of cranial nerve recovery in 33 cases.

BACKGROUND: Superior orbital fissure syndrome is a rare complication that occurs in association with craniofacial trauma. The characteristics of superior orbital fissure syndrome are attributable to a constellation of cranial nerve III, IV, and VI palsies. This is the largest series describing traumatic superior orbital fissure syndrome that assesses the recovery of individual cranial nerve function after treatment. METHODS: In a review from 1988 to 2002, 33 patients with superior orbital fissure syndrome were identified from 11,284 patients (0.3 percent) with skull and facial fractures. Severity of cranial nerve injury and functional recovery were evaluated by extraocular muscle movement. Patients were evaluated on average 6 days after initial injury, and average follow-up was 11.8 months. RESULTS: There were 23 male patients. The average age was 31 years. The major mechanism of injury was motorcycle accident (67 percent). Twenty-two received conservative treatment, five were treated with steroids, and six patients underwent surgical decompression of the superior orbital fissure. After initial injury, cranial nerve VI suffered the most damage, whereas cranial nerve IV sustained the least. In the first 3 months, recovery was greatest in cranial nerve VI. At 9 months, function was lowest in cranial nerve VI and highest in cranial nerve IV. Eight patients (24 percent) had complete recovery of all cranial nerves. Functional recovery of all cranial nerves reached a plateau at 6 months after trauma. CONCLUSIONS: Cranial nerve IV suffered the least injury, whereas cranial nerve VI experienced the most neurologic deficits. Cranial nerve palsies improved to their final recovery endpoints by 6 months. Surgical decompression is considered when there is evidence of bony compression of the superior orbital fissure.

Frontal sinus fractures: a treatment algorithm and assessment of outcomes based on 78 clinical cases.

BACKGROUND: The purposes of this article were to retrospectively review frontal sinus fractures at the authors' center, to assess the final outcomes, and to establish a treatment algorithm. METHODS: A retrospective chart review was performed on 78 consecutive frontal sinus fractures treated by the same surgeon between January 1, 1994, and January 1, 2002. RESULTS: In this study, 57.7 percent of fractures occurred as a result of motorcycle accidents and 75.6 percent of those patients were not wearing helmets at the time of injury. The use of helmets did not significantly affect the fracture pattern. Frontal sinus fractures were commonly associated with orbital fractures (71 percent), intracranial injuries (39 percent), and severe ophthalmic injuries (26 percent). Associated injuries were more common when the fractures involved the posterior tables. The method of management comprised four groups: no surgical intervention (n = 6), open reduction and internal fixation of the anterior table with sinus preservation (n = 40), partial sinus obliteration (n = 18), and cranialization (n = 14). The complication rate was 16.7 percent (n = 13), including postoperative cerebrospinal fluid leaks (n = 6), wound infections (n = 4), meningitis (n = 1), sinusitis (n = 1), and pyomucocele (n = 1). CONCLUSIONS: Involvement of the nasofrontal duct and persistence of cerebrospinal fluid leaks are two key determinants of the treatment algorithm. The amount of displacement of the posterior table has not been found to be a key determinant of the need for surgical intervention. When the sinus is to be obliterated, partial obliteration can achieve a good result, with limited sinus complication and minimal donor-site morbidity.

Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia.

This prospective study was designed to compare the efficacy of ondansetron with granisetron in terms of complete emesis control and time spent in an ambulatory care setting in children with acute lymphoblastic leukemia (ALL) undergoing moderately emetogenic cyclophosphamide-based chemotherapy. The costs for both treatments are also examined. A total of 33 children (mean age: 7.8 +/- 4.9 year) were studied during 66 chemotherapy cycles. Analysis was based on 33 courses of a single oral dose of granisetron and 33 courses of ondansetron incorporating 2 intravenous doses of ondansetron 0.15 mg/kg followed by 1 dose of the same dosage orally. There was no significant difference between the 2 treatments in terms of overall efficacy (McNemar's chi-square test). Twenty of 33 patients (60.6%) receiving granisetron and 15 of 33 patients (45.5%) receiving ondansetron experienced no emesis 24 h after chemotherapy (p = .227). Boys experienced greater rates of vomiting than did girls despite antiemetic treatment; however, no apparent reason for the gender discrepancy was noted. Both antiemetic regimens have similar antiemetic efficacy for treating the moderately emetogenic effects associated with cyclophosphamide-based chemotherapy. It is possible that the granisetron regimen may be preferable because it is simpler to administer and more cost-effective.